Analystreport

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at HC Wainwright from $144.00 to $157.00. They now have a "buy" rating on the stock.

Ligand Pharmaceuticals Incorporated  (LGND) 
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.ligand.com